Navigation Links
Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
Date:9/18/2013

NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development.  Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as supporting capital raising and business development activities.

"Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium's corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph.D., MBA, President and CEO of Actinium.  "Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company's lead candidates Iomab-B and Actimab-A."

"I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer.  Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies.  Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years.   Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation.  He has more than 20 years of finance and accounting experience.  Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Contact:
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
2. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
3. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
4. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
5. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
8. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
9. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017  In 2016, Embodied Labs ... pitch competition and came away with $25,000 in ... described by Forbes as "entering the life of another" ... as teaching "empathy to medical professionals in an entirely ... recently named a finalist for the Department of Education,s ...
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
Breaking Medicine Technology:
(Date:6/27/2017)... Philadelphia PA and London UK (PRWEB) , ... June 27, 2017 ... ... for applying to a clinical study is whether they can trust the sponsor to ... competitive, it is vital that sponsors and CROs establish payment strategies that encourage sites ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... Dermatologic Surgery Association’s SUNucate efforts, Louisiana became the sixth state to pass ... With Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan Agency, ... services to residents of southern New Hampshire, is teaming up with the New ... hunger and homelessness in the region. , New Horizons for New Hampshire provides ...
(Date:6/27/2017)... CT (PRWEB) , ... June 27, 2017 , ... Dr. ... the recent renovation of his practice, Advanced Periodontics and Dental Implant Center of Connecticut. ... increased the administrative and waiting areas. The renovations are intended to improve patient comfort ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
Breaking Medicine News(10 mins):